. Author manuscript; available in PMC: 2019 Apr 29.

Published in final edited form as: Cancer. 2019 Jan 15;125(6):843–853. doi: 10.1002/cncr.31838

TABLE 3.

Characteristics of the Included Studies Targeting Prostate Cancer

							Screening Proportion: No./Total No. (%)
Reference	Study Type	Size	Population	Intervention	Comparator	Primary Outcomes	HIV Population	HIV Non-Population	Quality
Shiels 2010¹⁶	Cohort study	N = 50,036 participants (721 HIV, 49,315 non-HIV)	HIV-positive, low-income men aged >40 y in Baltimore, MD, with any baseline cancer risk	Prostate cancer screening using at least 1 PSA test	External HIV-negative general population	Prostate cancer incidence and screening proportions	135/721 (19)	28,109/49,315 (57)	Poor
Marcus 2014¹⁷	Cohort study	N = 200,223 participants (17,424 HIV, 182,799 non-HIV)	HIV-positive men aged ≤55 y enrolled in Kaiser Permanente in the United States with any baseline cancer risk	Prostate cancer screening using at least 1 PSA test	HIV-negative men enrolled in Kaiser Permanente	Prostate cancer incidence and screening proportions	15,856/17,424 (91)	157,207/182,799 (86)	Fair

Abbreviations: HIV, human immunodeficiency virus; PSA, prostate-specific antigen.